Sosei Heptares Entered into a Research Collaboration and Option to License Agreement with AbbVie for Novel Therapies to Treat Neurological Diseases
- Sosei Heptares to receive $40M up front, ~$40M in near-term research milestones for the next 3yrs., ~$1.2B in option, development & commercial milestones along with royalties
- Sosei Heptares will be responsible to conduct & fund R&D activities upon the completion of IND-enabling studies. AbbVie has an exclusive license option for ~3 programs & will lead the clinical, regulatory & commercial development
- The new agreement was based upon the June 2020 agreement b/w Sosei Heptares & AbbVie for novel small molecules in inflammatory & autoimmune diseases. The new agreement will use Sosei Heptares’ StaR technology & SBDD platform with AbbVie’s extensive neuroscience & disease area expertise for small molecules that modulate novel GPCR targets in neurological disease
Ref: GlobeNewswire | Image: Sosei Heptares
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.